BR112015007637A2 - oligo rna de dupla hélice específico para amfiregulina, estrutura de oligo rna de dupla hélice e composição para prevenir ou tratar doenças respiratórias contendo o mesmo - Google Patents
oligo rna de dupla hélice específico para amfiregulina, estrutura de oligo rna de dupla hélice e composição para prevenir ou tratar doenças respiratórias contendo o mesmoInfo
- Publication number
- BR112015007637A2 BR112015007637A2 BR112015007637A BR112015007637A BR112015007637A2 BR 112015007637 A2 BR112015007637 A2 BR 112015007637A2 BR 112015007637 A BR112015007637 A BR 112015007637A BR 112015007637 A BR112015007637 A BR 112015007637A BR 112015007637 A2 BR112015007637 A2 BR 112015007637A2
- Authority
- BR
- Brazil
- Prior art keywords
- stranded
- double
- amphyregulin
- oligo
- oligo rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo oligo rna de dupla hƒlice especêfico para amfiregulina, estrutura de oligo rna de dupla hƒlice e composi‚ìo para prevenir ou tratar doen‚as respiratîrias contendo o mesmo, refere-se a um oligo sirna de fita dupla espec’fico de anfiregulina, que pode inibir a express‹o de anfiregulina com alta efici�ncia e ser efetivamente usado para a preven�‹o ou tratamento de doen�as respirat—rias. alžm disso, a inven�‹o compreende compostos hidrof’licos e hidrof—bicos, ligados ao oligo sirna de fita dupla espec’fico de anfiregulina por liga�‹o covalente œnica ou liga�‹o covalente mediada por ligante, de modo a aumentar a estabilidade in vivo e a efici�ncia de libera�‹o intracelular do oligo sirna de fita dupla, e para nanopart’culas compostas de estruturas de oligo sirna. a estrutura de oligo sirna de fita dupla espec’fico de anfiregulina, de acordo com a presente inven�‹o, pode aumentar a estabilidade do oligo sirna de fita dupla espec’fico sem comprometer a fun�‹o do oligo sirna de fita dupla espec’fico para anfiregulina e, ao mesmo tempo, pode efetivamente aumentar a permeabilidade de membrana do oligo sirna de fita dupla. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120110559 | 2012-10-05 | ||
PCT/KR2013/008949 WO2014054927A1 (ko) | 2012-10-05 | 2013-10-07 | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015007637A2 true BR112015007637A2 (pt) | 2017-08-08 |
Family
ID=50435202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015007637A BR112015007637A2 (pt) | 2012-10-05 | 2013-10-07 | oligo rna de dupla hélice específico para amfiregulina, estrutura de oligo rna de dupla hélice e composição para prevenir ou tratar doenças respiratórias contendo o mesmo |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150259690A1 (pt) |
EP (1) | EP2905337A4 (pt) |
JP (1) | JP2015532100A (pt) |
KR (1) | KR20150064065A (pt) |
CN (1) | CN104781403A (pt) |
AU (1) | AU2013325384A1 (pt) |
BR (1) | BR112015007637A2 (pt) |
CA (1) | CA2887069A1 (pt) |
WO (1) | WO2014054927A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101867414B1 (ko) * | 2013-07-05 | 2018-06-14 | (주)바이오니아 | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 |
CN106459974A (zh) * | 2014-04-04 | 2017-02-22 | 柏业公司 | 新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物 |
CN108220320A (zh) * | 2018-02-12 | 2018-06-29 | 武汉伊艾博科技有限公司 | 人双调蛋白克隆至人工改造的表达载体pGEX-4T-1及其原核可溶性表达的研究 |
CA3101320A1 (en) * | 2018-05-25 | 2019-11-28 | Bioneer Corporation | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5034323A (en) | 1989-03-30 | 1991-07-23 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
CA2463595A1 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of bcl2 gene expression using short interfering nucleic acid (sina) |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
AU2006280600B2 (en) | 2005-08-17 | 2012-01-19 | Bioneer Corporation | Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
WO2008044068A2 (en) * | 2006-10-11 | 2008-04-17 | Fusion Antibodies Limited | Combination therapy |
WO2008090850A1 (ja) * | 2007-01-22 | 2008-07-31 | Juridical Foundation Osaka Industrial Promotion Organization | 抗癌剤の効果増強剤 |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
EP2561356B1 (en) * | 2010-04-18 | 2016-08-03 | Yeda Research and Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
KR101241852B1 (ko) * | 2012-06-28 | 2013-03-11 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
-
2013
- 2013-10-07 EP EP13843342.0A patent/EP2905337A4/en not_active Withdrawn
- 2013-10-07 JP JP2015535571A patent/JP2015532100A/ja active Pending
- 2013-10-07 US US14/433,627 patent/US20150259690A1/en not_active Abandoned
- 2013-10-07 BR BR112015007637A patent/BR112015007637A2/pt not_active IP Right Cessation
- 2013-10-07 CA CA2887069A patent/CA2887069A1/en not_active Abandoned
- 2013-10-07 WO PCT/KR2013/008949 patent/WO2014054927A1/ko active Application Filing
- 2013-10-07 AU AU2013325384A patent/AU2013325384A1/en not_active Abandoned
- 2013-10-07 KR KR1020157008814A patent/KR20150064065A/ko not_active Application Discontinuation
- 2013-10-07 CN CN201380058056.6A patent/CN104781403A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2905337A1 (en) | 2015-08-12 |
CN104781403A (zh) | 2015-07-15 |
EP2905337A4 (en) | 2016-10-12 |
JP2015532100A (ja) | 2015-11-09 |
AU2013325384A1 (en) | 2015-04-30 |
KR20150064065A (ko) | 2015-06-10 |
US20150259690A1 (en) | 2015-09-17 |
CA2887069A1 (en) | 2014-04-10 |
WO2014054927A1 (ko) | 2014-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
WO2014022739A3 (en) | Modified rnai agents | |
CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
PE20090064A1 (es) | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende | |
UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
BR112015005940A2 (pt) | processo para a preparação de nanopartículas terapêuticas | |
BR112014033004A2 (pt) | oligonucleotídeo para tratamento de pacientes com distrofia muscular | |
SG10201804960RA (en) | Complement component irna compositions and methods of use thereof | |
UA118649C2 (uk) | ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR) | |
BR112015007637A2 (pt) | oligo rna de dupla hélice específico para amfiregulina, estrutura de oligo rna de dupla hélice e composição para prevenir ou tratar doenças respiratórias contendo o mesmo | |
WO2013074974A3 (en) | Modified rnai agents | |
NI201200181A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
MX2009002090A (es) | Sustancias sanitarias, desinfectantes, y/o esterilizantes acuosas con bajo contenido de peróxido de hidrógeno. | |
BR112014004544A2 (pt) | modificação com peg de nanopartículas com h-fosfonatos | |
MY161495A (en) | Virus like particle compositions and methods of use | |
ECSP11010803A (es) | Compuestos de cobre nanoparticulados | |
BRPI1007325A2 (pt) | "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo." | |
WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
WO2010067078A8 (en) | 3,6-disubstituted xanthylium salts | |
BR112013020816A2 (pt) | substrato sólido poroso desintegrável para aplicações para cuidados pessoais com a saúde | |
CR20120082A (es) | Conservantes de derivados de quitina | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
GEP201706606B (en) | Water-in-oil type emulsion for treating a disease of the eye | |
WO2012040331A3 (en) | Multistage nanoparticles | |
CL2013002107A1 (es) | Uso de un fluido viscoelastico acuoso para producir un producto medicinal para el tratamiento quirurjico del ojo, que comprende a) por lo menos un polimero de aumento de la viscosidad a una concentracion de 0,01-30%, b) un valor de ph que oscila de 6 a 8,5 y c) una osmolaridad que oscila de 200 a 400 mosmol/l. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |